Table 3.
ERβ expression in the tolterodine and intravaginal estradiol groups and changes from baseline to 12 weeks
| Group | ERβ expression | 12-week Follow-up ERβ expression | t/F | p | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
| 0 (%) | 1 (%) | 2 (%) | 3 (%) | 0 (%) | 1 (%) | 2 (%) | 3 (%) | |||
| Tolterodine (n = 30) | 16 (53) | 12 (40) | 13.542 | 2 (7) | 0 (0) | 17 (57) | 13 (43) | 0 (0) | 0 (0) | 0.165 |
| Intravaginal Estrogen (n = 28) | 14 (50) | 11 (39) | 6.821 | 2 (8) | 1 (3) | 5 (17) | 13 (46) | 8 (29) | 2 (8) | < 0.014* |
| p | 0.485 | 0.001 | ||||||||
| t/F | 12.587 | 1.685 | p (t/F) | |||||||
ERβ, estrogen receptor β.
*
Compared to the 12-week follow-up within Intravaginal Estrogen group.